Molecular Cancer Therapeutics strives to be the top choice for publishing the best science in the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanism of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms. While the journal's main focus is on small molecule and protein drugs, other molecular entities may be considered.